Although accumulative literature supports the beneficial effects of plant extracts and naturally derived compounds against diabetes (Hung et al., 2012
Int J Obes 46(1):2129 Reis-Barbosa PH, Marcondes-de-Castro IA, de Marinho T, S, Aguila MB, Mandarim-de-Lacerda CA, (2022) The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice
Ive observed that there are 5 obstacles patients experience with these medications as treatments for obesity and diabetes: Cost of the meds Side effects and tolerability Fear of needles Concerns about safety The moral failing of needing a medication Oral GLP1 drugs like orforglipron (Foundayo) and Wegovy work almost as well as the injectable version of these drugs The FDA just approved oral Foundayo for the treatment of obesity based on the results of the ATTAIN-1 trial, recently published in NEJM
It is associated with a wide variety of conditions that include physiologic changes, inflammatory diseases, hormonal disorders, drugs and chemicals, benign and malignant neoplasm, and other non-melanotic conditions
When Treatment Plans Change Your lab results help your doctor make decisions about your care
Ramaekers VT, Blau N
:max_bytes(150000):strip_icc()/VWH-GettyImages-2178836417-ee318a41780b44e9af3ff47de83fafd7.jpg)
